Skip to content
Screener

ANI Pharmaceuticals ANIP Q2 2026 earnings

Reported August 7, 2026 · Before market open

Revenue$266.0MBeat by $5.9M
EPS$2.21Beat by $0.17
Revenue estimate$260.1M
EPS estimate$2.04
“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history. Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel's sizable multi-year growth opportunity.”
Nikhil Lalwani

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$280.1M
EPS estimate$2.12

Financials

Q2 2026

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.69B-18.3%
Enterprise value$1.63B-24.6%
P/E15.6×—
P/S1.7×-1.0×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%—
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Segments

By product

See full
Cortrophin Gel$117.1M+43.5%
Generic pharmaceutical products$99.1M+9.7%
ILUVIEN and YUTIQ$18.7M-16.1%
Brand royalties and other revenues$17.7M—
Brands$11.8M-10.5%

By segment

See full
Rare Disease and Brands$165.4M+41.2%
Generics and Other$100.7M+6.8%

FAQ

When did ANI Pharmaceuticals report Q2 2026 earnings?
ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings on August 7, 2026 before market open.
What were ANI Pharmaceuticals's Q2 2026 revenue and EPS?
ANI Pharmaceuticals reported revenue of $266.0M and eps of $2.21 for Q2 2026.
Did ANI Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $260.1M by $5.9M. EPS beat the consensus estimate of $2.04 by $0.17.
How did ANI Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 25.9% from $211.4M a year earlier and eps grew 22.8% from $1.80.
Where can I find ANI Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001023024-26-000068) and the 10-Q periodic report (0001023024-26-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.